

Appendix: schedule of clinical, laboratory and adherence assessments for rifampin therapy.

Actions	Baseline	Month 1	Month 2	Month 3	Month 4
Medical evaluation	✓	If needed NOTE: Indicated for clients with liver toxicity, thrombocytopenia and/or signs/symptoms of TB or for clients who require chest x-ray at treatment completion.			
Clinical assessment		✓	✓	✓	✓
Adherence assessment		✓	✓	✓	✓
Chest x-ray	✓ ∅				**
Weight [§]	✓	✓	✓	✓	✓
AST, Total Bilirubin ^Φ , CBC ^Φ (NOTE: Testing of clients under 16 years is done as recommended by TB Services)					
16 to 34	✓				
35 to 50	✓	✓			
> 50	✓	✓	✓	✓	✓
Any age with risk factors for drug-induced hepatitis ^Ψ	✓	✓	✓	✓	✓

∅ A CXR done within the last 6 months may be used for baseline assessment, unless the client is immune compromised, then a CXR within the last 3 months is required.

** Generally only required for clients with TB-related abnormalities noted on their initial chest x-rays.

Appendix: schedule of clinical, laboratory and adherence assessments for isoniazid therapy.

Actions	Baseline	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8	Month 9
Medical evaluation	✓	If needed NOTE: Indicated for clients with liver toxicity and/or signs/symptoms of TB or for clients who require chest x-ray at treatment completion.								
Clinical assessment		✓	✓	✓	✓	✓	✓	✓	✓	✓
Adherence assessment		✓	✓	✓	✓	✓	✓	✓	✓	✓
Chest x-ray	✓ ∅									**
Weight [§]	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
AST (NOTE: Testing of clients under 16 is done as recommended by TB Services)										
16 to 34	✓									
35 to 50	✓	✓								
> 50	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Any age with risk factors for drug-induced hepatitis ^Ψ	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

** Generally only required for clients with TB-related abnormalities noted on their initial chest x-rays.

∅ A CXR done within the last 6 months may be used for baseline assessment, unless the client is immune compromised, then a CXR within the last 3 months is required.

Supplementary Appendix:

Comparison of participants completing therapy versus non-completion

Variable	Completed treatment	Did not complete treatment	p-value
Gender	n=289	n=69	0.754
Female	156 (54.0)	40 (58.0)	
Male	132 (45.7)	29 (42.0)	
Transgender	1 (0.3)	0	
Median age in years (IQR)	43 (34 - 52)	43 (33 - 51)	0.990
Alcohol use	n=269	n=66	0.746
None	158 (58.7)	39 (59.0)	
1-2 times monthly	84 (31.2)	18 (27.3)	
2-3 times weekly	22 (8.2)	8 (12.1)	
Daily	5 (1.9)	1 (1.5)	
Recreational drug use	n=261	n=66	0.672
None	251 (96.2)	65 (98.5)	
1-2 times monthly	4 (1.5)	1 (1.5)	
2-3 times weekly	3 (1.1)	0	
Daily	3 (1.1)	0	
Highest level of education attained	n=269	n=66	0.431
No formal education	2 (0.7)	2 (3.0)	
Elementary or junior high school	8 (3.0)	1 (1.5)	
High school	46 (17.1)	14 (21.2)	
College/trade school	102 (37.9)	26 (39.4)	
University	111 (41.3)	23 (34.8)	
Average annual income, Canadian dollars	n=232	n=53	0.836
< \$10,000	48 (20.7)	10 (18.9)	
\$10,000-\$49,999	129 (55.6)	33 (62.3)	
\$50,000-\$99,999	49 (21.1)	9 (17.0)	
> \$100,000	6 (2.6)	1 (1.9)	
Region of birth	n=286	n=69	0.838
Southeast Asia & Oceania	101 (35.3)	28 (40.6)	
South Asia & the Middle East	62 (21.7)	11 (15.9)	
Canada	52 (18.2)	9 (13.0)	
Eastern Asia	40 (14.0)	12 (17.4)	
Africa	18 (6.3)	3 (4.3)	
Europe	6 (2.1)	3 (4.3)	
Central America	4 (1.4)	2 (2.9)	
USA	3 (1.0)	1 (1.4)	
Treatment regimen	n=289	n=69	0.300
9-INH	195 (67.5)	51 (73.9)	
4-RIF	94 (32.5)	18 (26.1)	